Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Ezutromid in Pediatric DMD
NCT02383511Phase 1Completed
- Sponsor
- Summit Therapeutics
- Start
- Feb 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ezutromid in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Summit Therapeutics. Primary endpoint: Plasma concentration of SMT C1100 at 28 days. Started Feb 2015; status: completed.
02
Drugs
ezutromid
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02383511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383511.